Luca Dezzani is the Vice President of U.S. Medical Affairs for Eisai’s Oncology Business Group. He is responsible for Medical Affairs strategy for the company's oncology portfolio of both...

Merck and Eisai join forces to help tackle some of the most challenging types of cancers. It’s sometimes said that the whole is greater than the sum of its parts. That’s why Merck and Eisai joined together in 2018 to leverage each other’s unique strengths and diverse backgrounds to help advance cancer research.

Dr. Lynn Kramer, CMO, Eisai Neurology, discusses the FDA’s regulatory pathway allowing for the extrapolation of clinical data from adjunctive to monotherapy use in partial-onset seizures, which improves access to epilepsy treatments.

Human genetics is transforming the way new drugs are discovered, giving unprecedented hope for delivering better medicines

ResponseABILITY is brought to you by Eisai to help shed light on the impact of treatment response on patients with cancer and their families and the physicians who treat them